Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIDE
NCT06718686Phase 2Recruiting
- Sponsor
- Jasmohan Bajaj
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rifaximin in Alzheimer's disease (AD) and vascular dementia (2 arms), sponsored by Jasmohan Bajaj. Primary endpoints: Change in stool and serum short-chain fatty acid levels at 10 weeks and Change in bile acids in stool and serum at 10 weeks. Started Dec 2024; status: recruiting.
02
Drugs
rifaximin
03
Conditions
Alzheimer's disease (AD)vascular dementia
Beyond the preview
Go deeper on NCT06718686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718686.